Purchase this article with an account.
S.-W. Kim, K. Huh, J. Oh; In vitro Effect of Combined Dexamethasone and Bevacizumab Treatment on the Viability of Human Retinal Pigment Epithelial Cells After Photodynamic Therapy With Verteporfin. Invest. Ophthalmol. Vis. Sci. 2008;49(13):477.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the in vitro effect of combined dexamethasone and bevacizumab treatment with photodynamic therapy (PDT) using verteporfin on the cell viability of the retinal pigment epithelial (RPE) cells.
Human retinal pigment epithelial cells (ARPE-19) were treated with two different concentrations of dexamethasone (0.1 and 0.2 mg/ml) and bevacizumab (0.125 and 0.25 mg/ml) in conjunction with or without verteporfin PDT. Cell viability was measured using cell count (%) and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay at 2 hours, 24 hours, and 48 hours after combined therapy.
The cell viabilities of ARPE-19 cells, treated with dexamethasone or bevacizumab only, were not significantly different (P > 0.05) from those of untreated controls at all time points and concentrations irrespective of PDT. The lack of cytotoxic effect of combined 0.1 mg/ml dexamethasone and 0.125mg/ml bevacizumab treatment with or without PDT on ARPE-19 cells could be observed at all periods. The MTT assay decreased to 91.3 ± 6.0% (p=0.009), 94.7 ± 4.7% (p=0.045), and 92.9 ± 6.2% (p=0.034) respectively, after 2 hours, 24 hours, and 48 hours of direct exposure to both 0.2mg/ml dexamethasone and 0.25 mg/ml bevacizumab with PDT. The number of viable cells also decreased by 93.4 ± 3.0% (p=0.032), 90.7 ± 6.0% (p=0.001), and 93.5 ± 3.9% (p=0.034) respectively, after 2 hours, 24 hours, and 48 hours of direct exposure to both dexamethasone 0.2 mg/ml and 0.25mg/ml bevacizumab with PDT.
In vitro, 0.2 mg/ml dexamethasone and 0.25mg/ml bevacizumab combination therapy, usually used for treatment of choroidal neovascularization, is toxic to ARPE-19 cells irrespective of PDT.
This PDF is available to Subscribers Only